R-7050,303997-35-5

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

R-7050

CAS No. : 303997-35-5

MCE 国际站：R-7050

产品活性：R-7050 (TNF-α Antagonist III) 是一种肿瘤坏死因子受体 (TNFR) 拮抗剂，对 TNFα 具有更高选择性。

研究领域：Apoptosis

作用靶点：TNF Receptor

In Vitro: R-7050 (TNF-α Antagonist III) is a potent and fully reversible hit with greater selectivity toward TNFα. In TNFα-induced intercellular adhesion molecule 1 (ICAM-1) expression, R-7050 inhibition potency (EC₅₀=0.63 μM) is 2- to 3-fold greater than EC₅₀ for IL-1β-induced ICAM-1 expression (EC₅₀=1.45 2 μM). R-7050 inhibits phosphorylation of both the JNK pathway (MKK4, JNKs, and ATF2) and p38 pathway (MKK3/6, p38, and MAPKAP2). R-7050 is a cell-permeable triazoloquinoxaline compound that selectively inhibits TNF-α induced cellular signaling. Unlike biologic TNF inhibitors (e.g. Infliximab, Etanercept, Adalimumab) that directly bind TNF-α and function as decoy receptors, R-7050 does not affect binding of TNF-α to TNFR. In contrast, R-7050 selectively inhibits the association of TNFR with intracellular adaptor molecules (e.g. TRADD, RIP), limits receptor internalization, and prevents subsequent cellular responses after TNF-α binding.

In Vivo: R-7050 (TNF-α Antagonist III) (6 mg/kg) reduces Evans blue extravasation to 28.7±5.9 μg and 30.3±1.9 μg Evans blue/g brain tissue when administered at 0.5 h or 2 h post-ICH, respectively (p<0.05 and p<0.01 vs ICH, respectively; not significantly different from sham). Brain water content, a measure of brain edema, increases from 75.6±0.3% in sham-operated mice to 81.5±0.5% at 24h post-ICH (p<0.05 vs. sham). 6, 12, or 18 mg/kg R-7050 reduces brain water content to 78.5±0.3%, 78.3±0.3%, or 79.3±0.5%, respectively (all treatments p<0.05 vs. ICH; treatments not significantly different from each other). Notably, mice treated with 18 mg/kg exhibit a reduction in general activity/locomotion. As is observed with Evans blue extravasation, R-7050 (6 mg/kg) significantly reduces brain water content after ICH. Administration of R-7050 at 0.5h or 2h post-ICH attenuates brain water content to levels observed in sham-operated mice (p<0.05 vs ICH, not significantly different from sham).

相关产品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Immunology/Inflammation Compound Library  |  Anti-Cancer Compound Library  |  Pyroptosis Compound Library  |  Angiogenesis-Related Compound Library  |  Targeted Diversity Library  |  Antidepressant Compound Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Cancer Stem Cells Compound Library  |  Pain-Related Compound Library  |  Mitochondrial Protection Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Autoimmune Disease Compound Library  |  Highly Selective Inhibitors Library  |  Cytokine Inhibitors Library  |  Resatorvid  |  Shikonin  |  Infliximab  |  Fisetin  |  Adalimumab  |  Etanercept  |  N-Formyl-Met-Leu-Phe  |  QNZ  |  Theophylline  |  Apremilast  |  C25-140  |  UCB-9260  |  Diprovocim  |  Muscone  |  Brentuximab vedotin  |  TRAF-STOP inhibitor 6877002  |  Certolizumab pegol  |  Astilbin  |  Forsythoside B  |  Geraniin  |  Semapimod tetrahydrochloride  |  Sinensetin  |  HS-276  |  DRI-C21045  |  Belimumab  |  Mulberroside A  |  Adalimumab (anti-TNF-α)  |  Tryptanthrin  |  SPD304  |  KR-33493

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds